Monkeypox Vaccine Market Report by Type (Replication-competent, Replication-deficient), Route of Administration (Subcutaneous, Percutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Monkeypox Vaccine Market Report by Type (Replication-competent, Replication-deficient), Route of Administration (Subcutaneous, Percutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A6251
Buy Now

Market Overview:

The global monkeypox vaccine market size reached US$ 86.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032. The growing international health organizations and government initiatives due to the increasing spread of infectious diseases, the accelerating number of awareness campaigns, and continuous advancements in personalized medicine are some of the major factors propelling the market.

Report Attribute
Key Statistics
Base Year
Forecast Years
Historical Years
Market Size in 2023 US$ 86.6 Million
Market Forecast in 2032 US$ 421.8 Million
Market Growth Rate 2024-2032 18.85%

The monkeypox vaccine is a medical solution used to protect against monkeypox, a rare viral disease similar to smallpox. It is caused by the monkeypox virus, and can have serious health implications, particularly in regions where it is endemic. The vaccine leverages the same fundamental principles as the smallpox vaccine, as the viruses are closely related. By introducing a small, controlled portion of the virus into the body, the vaccine stimulates the immune system to produce antibodies. These antibodies, in turn, provide immunity and can effectively fend off a full-blown infection if the individual is exposed to the monkeypox virus in the future. Administering the monkeypox vaccine, particularly in vulnerable regions, plays a vital role in preventing outbreaks and controlling the spread of the disease. It stands as an essential tool in global health efforts.

The increasing incidence and spread of monkeypox among the masses majorly drive the market. The spread of infectious diseases such as monkeypox has prompted international health organizations and governments to be more proactive in containment and prevention. Therefore, this is significantly supporting the market. As awareness about monkeypox spreads, public understanding of the disease and its potential consequences increases. Governments, healthcare organizations, and NGOs often conduct awareness campaigns, educating people about the benefits of vaccination. This, in turn, fuels demand for the vaccine, driving market growth. In addition, rising international travel and globalization have created potential pathways for diseases, including monkeypox to spread across borders. The demand for vaccines as a precautionary measure for travelers, particularly to regions where the disease is more prevalent, can boost the market for monkeypox vaccines. Apart from this, advances in personalized medicine enable the development of vaccines that are tailored to specific populations or even individuals. Customized research that considers genetic, demographic, and environmental factors can lead to more effective and targeted vaccines, thereby stimulating market growth. Moreover, the incorporation of the monkeypox vaccine into existing routine immunization programs to ensure broader coverage is creating a positive market outlook.

Monkeypox Vaccine Market Trends/Drivers:

Regulatory Support and Government Initiatives

Governments and regulatory bodies play a crucial role in the monkeypox vaccine industry by providing support through policies, funding, and collaborations. Understanding the potential health risks of monkeypox, several nations have taken proactive measures to incentivize vaccine development. This includes grants, subsidies, tax incentives, and simplified approval processes. Collaborative efforts between governments, international health organizations, and private sectors are aimed at research, production, and distribution of vaccines. Along with this, governmental support also extends to creating awareness and educational programs that underline the importance of vaccination. Regulatory compliance ensures that vaccines meet the required safety and efficacy standards. The alignment between public policy and industry goals is fostering an environment conducive to growth, promoting public-private partnerships, and enhancing the overall reach and effectiveness of the monkeypox vaccine.

Increasing Healthcare Infrastructure and Accessibility

The expansion of healthcare infrastructure globally is a significant driver for the monkeypox vaccine industry. With the establishment of new healthcare facilities, improved supply chain management, and enhanced logistical support, vaccines are now more accessible to previously underserved populations. Efforts are being made to ensure that vaccines reach remote areas, particularly in regions where monkeypox is endemic. Collaborative efforts between governments, NGOs, and pharmaceutical companies focus on providing affordable vaccines to those who need them most. Strategies like tiered pricing, bulk purchasing agreements, and public funding are implemented to make vaccines financially accessible. These initiatives ensure that vaccines are available and affordable and that vaccination campaigns can be executed effectively. The enhancement of healthcare infrastructure, aligned with the global commitment to health equality, is amplifying the reach and impact of the monkeypox vaccine industry.

Technological Advancements in Vaccine Development

The ongoing technological advancements in biotechnology and pharmaceuticals have significantly impacted the monkeypox vaccine industry. Enhanced research methodologies, new vaccine delivery systems, and the integration of artificial intelligence in drug development are driving innovation. With growing knowledge of viral genomics and the monkeypox virus's structure, new vaccines can be developed more effectively. Improved manufacturing processes have also streamlined vaccine production, making it more efficient and cost-effective. In addition, partnerships between research institutions, pharmaceutical companies, and health organizations are fostering knowledge-sharing, further facilitating vaccine development. Technological innovations accelerate the vaccine's time-to-market and improve its efficacy, safety, and accessibility. The adoption of cutting-edge technology in the vaccine industry is a key driver for growth, reflecting an increasing commitment to combat and contain infectious diseases.




Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Monkeypox Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global monkeypox vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, route of administration, distribution channel and end user.

Breakup by Type:




Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Replication-competent
  • Replication-deficient

The report has provided a detailed breakup and analysis of the market based on the type. This includes replication-competent and replication-deficient.

The replication-competent type within the monkeypox vaccine industry is influenced by the increasing incidence of monkeypox outbreaks and the potential threat of zoonotic transmission to humans. Additionally, advancements in biotechnology and vaccine development techniques are fostering the creation of safer and more efficient replication-competent vaccines. Government initiatives and funding to combat emerging infectious diseases further bolster market growth. Moreover, collaborations between research institutions, pharmaceutical companies, and healthcare organizations are enhancing the R&D efforts for improved monkeypox vaccines.

On the other hand, the rising prevalence of monkeypox infections and the potential cross-species transmission underline the imperative need for robust preventive measures, driving the demand for effective vaccines. Ongoing advancements in biotechnology and vaccine formulation techniques play a pivotal role in fostering the development of safer and more targeted replication-deficient vaccines. Furthermore, collaborative efforts between research institutions, pharmaceutical enterprises, and healthcare bodies are accelerating the research and development endeavors for enhanced monkeypox vaccines.

Breakup by Route of Administration:

  • Subcutaneous
  • Percutaneous

Subcutaneous hold the largest share in the market

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes subcutaneous and percutaneous. According to the report, subcutaneous accounted for the largest market share.

The subcutaneous route of administration is a pivotal driver within the monkeypox vaccine industry, influenced by the growing demand for optimized vaccine delivery methods that strike a balance between patient comfort and vaccine effectiveness. The subcutaneous route, characterized by its minimally invasive nature, offers a patient-friendly alternative that can enhance vaccination acceptance and coverage, particularly among sensitive populations. This demand is further fueled by the increasing emphasis on preventive healthcare and the urgency to curb infectious diseases. In addition, economic considerations also play a significant role in driving the preference for subcutaneous administration. The potential reduction in healthcare costs associated with streamlined vaccination procedures, decreased adverse events, and simplified logistics contribute to its market viability. Additionally, regulatory agencies' recognition of the subcutaneous route as a safe and effective administration method lends further impetus to its adoption. The industry's response to these drivers is steering research and development efforts toward optimizing the formulation and delivery of monkeypox vaccines through the subcutaneous route. This strategic alignment with healthcare trends and patient preferences positions subcutaneous administration as a key player in the ongoing fight against monkeypox and emerging infectious diseases.

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hospital pharmacy dominates the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, online pharmacy, and others. According to the report, hospital pharmacy represented the largest segment.

The hospital pharmacy distribution channel serves as a pivotal market driver within the monkeypox vaccine industry, propelled by the critical role of hospitals as primary healthcare providers. Hospitals stand as focal points for disease management and prevention, necessitating swift access to vaccines such as those for monkeypox. The trust associated with hospital-based healthcare encourages patients to seek vaccination within these settings, boosting demand. Moreover, the hospital pharmacy channel offers the advantage of professional oversight by pharmacists and healthcare providers, ensuring proper storage, handling, and administration of vaccines. Economically, hospital pharmacies benefit from bulk purchases and established supply chains, potentially leading to cost efficiencies. Government immunization programs often collaborate with hospitals for widespread vaccination campaigns, further driving the prominence of this channel. Regulatory compliance and quality assurance mechanisms intrinsic to hospital operations enhance the credibility of vaccines distributed through this route. As hospitals remain critical in the battle against infectious diseases, the hospital pharmacy distribution channel assumes a central role in ensuring the availability and accessibility of monkeypox vaccines.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals hold the largest share in the market

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.

Hospitals as end users constitute a fundamental market driver within the monkeypox vaccine industry, propelled by multifaceted dynamics. Firstly, hospitals play a central role in providing comprehensive healthcare services, including vaccination, making them key points of access for monkeypox vaccines. The inherent trust patients place in hospitals fosters higher acceptance rates and uptake of these preventive measures. Additionally, the potential for monkeypox outbreaks to lead to public health emergencies reinforces hospitals' importance in swift and effective vaccine administration. Along with this, collaborations between healthcare authorities and hospitals often drive mass vaccination campaigns, underscoring their role in disease containment. Furthermore, adherence to regulatory standards and quality control protocols inherent to hospital operations enhances the reliability and safety of vaccines distributed through this channel. As the industry aligns its efforts with hospital-based vaccination initiatives, it capitalizes on hospitals' strategic position to ensure the availability, accessibility, and proper administration of monkeypox vaccines, contributing significantly to public health safeguarding.

Breakup by Region:




To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest monkeypox vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest share.

The monkeypox vaccine industry in North America is fueled by the increasing awareness of emerging infectious diseases, including monkeypox. The potential risk of zoonotic transmission and cross-species infections accentuates the urgency for reliable vaccines. Along with this, government agencies and healthcare authorities prioritize public health preparedness, allocating resources to support research, development, and distribution of monkeypox vaccines. Moreover, the well-established healthcare infrastructure and regulatory framework in North America provide a conducive environment for vaccine development, ensuring safety and efficacy. Collaborative efforts between research institutions, pharmaceutical companies, and healthcare providers further accelerate advancements in the field. As the region's healthcare systems address these drivers, the monkeypox vaccine industry in North America stands poised to contribute significantly to disease prevention, bolstering public health resilience in the face of emerging threats.

Competitive Landscape:

The global monkeypox vaccine market is experiencing significant growth due to the escalating research, development, and strategic initiatives aimed at addressing the growing demand for effective preventive measures against monkeypox. Along with this, companies are investing in advanced biotechnological approaches to formulate vaccines that offer enhanced safety, efficacy, and coverage. Research and development efforts are focused on optimizing vaccine candidates to ensure robust immune responses and long-lasting protection. Additionally, manufacturers are collaborating with research institutions, governmental organizations, and healthcare bodies to expedite the vaccine development process. They are conducting clinical trials to demonstrate the safety and effectiveness of their vaccine candidates, with the goal of obtaining regulatory approvals for widespread distribution. Apart from R&D, companies are also working on establishing robust manufacturing and distribution networks to ensure the availability and accessibility of monkeypox vaccines. This includes optimizing production processes, securing supply chains, and partnering with distribution channels, such as hospitals and healthcare providers, to facilitate efficient vaccine delivery.

The report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Monkeypox Vaccine Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Type
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Types Covered Replication-Competent, Replication-Deficient
Route of Administrations Covered Subcutaneous, Percutaneous
Distribution Channels Covered Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
End Users Covered Hospitals, Clinics, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the monkeypox vaccine market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global monkeypox vaccine market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the monkeypox vaccine industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global monkeypox vaccine market was valued at US$ 86.6 Million in 2023.

We expect the global monkeypox vaccine market to exhibit a CAGR of 18.85% during 2024-2032.

The rising incidences of various chronic ailments and dermatology-related problems, such as eczema, along with the growing consumer awareness regarding disease prevention and the importance of immunization, are primarily driving the global monkeypox vaccine market.

The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to the vaccine for combating the spread of the coronavirus infection, thereby negatively impacting the global market for monkeypox vaccine.

Based on the route of administration, the global monkeypox vaccine market can be segmented into subcutaneous and percutaneous. Currently, subcutaneous holds the majority of the total market share.

Based on the distribution channel, the global monkeypox vaccine market has been divided into hospital pharmacy, retail pharmacy, online pharmacy, and others. Among these, hospital pharmacy currently exhibits a clear dominance in the market.

Based on the end user, the global monkeypox vaccine market can be categorized into hospitals, clinics, and others. Currently, hospitals account for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Monkeypox Vaccine Market Report by Type (Replication-competent, Replication-deficient), Route of Administration (Subcutaneous, Percutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More